CustomCustomCustomCustomCustomCustom
24 02, 2020

TAmiRNA at SOT 2020, 15-19 March 2020, Anaheim, California, USA

2023-03-10T10:52:49+01:00February 24th, 2020|biomarker, biomarkers, drug development, drug discovery, liquid biopsies, LMD, microRNAs, Personalized medicine|Comments Off on TAmiRNA at SOT 2020, 15-19 March 2020, Anaheim, California, USA

The sequencing advance allows genome scale analysis of miRNAs and promises a more efficient discovery approach for safety biomarkers, enabling retrospective analysis. Dr. Kseniya Khamina, TAmiRNA research scientist, will deliver a presentation on ‘Next-generation sequencing pipeline for genome-scale analysis of circulating microRNAs as discovery approach for safety biomarkers’ (P338) during the Biomarkers Poster Session on Day Two, CC Exhibit Hall, of the meeting. The poster was co-authored by TAmiRNA and researchers from the Functional Genomics Center Zurich, Eli Lilly and Company and Merck & Co. Take advantage, meet Kseniya and discuss our latest developments and how TAmiRNA's products and services can assist your business or make an appointment NOW!

Read More
5 11, 2019

Combining laser microdissection and microRNA expression profiling to unmask microRNA signatures in complex tissues

2023-03-10T10:56:26+01:00November 5th, 2019|biomarker, biomarkers, drug development, drug discovery, LMD, microRNAs, Personalized medicine, safety, Vivomicx|Comments Off on Combining laser microdissection and microRNA expression profiling to unmask microRNA signatures in complex tissues

We want to draw your attention to the latest publication with our partner Vivomicx. Together we have developed a combination of laser microdissection (LMD) and high quality qPCR, which enables the quantitative analysis of cell-type specific RNA expression in complex tissues. Using this protocol TAmiRNA & Vivomicx have been able to demonstrate: the profound difference of RNA expression between whole tumor and subsets of cells within the tumor and the large heterogeneity in RNA expression between colorectal* tumor compartments such as tumor, stroma and tumor endothelial cells. * Note: the technology can be utilized for almost any tissue sample. Our new approch allows to: Discover differential expression patterns between “healthy” and “diseased” tissues on the cellular level; [...]

Read More
30 04, 2019

TAmiRNA is part of the international IMI2 project “Translational Safety Biomarker Pipeline”

2023-03-10T11:01:16+01:00April 30th, 2019|biomarkers, drug development, drug discovery, exosomes, liquid biopsies, microRNAs, Personalized medicine, safety|Comments Off on TAmiRNA is part of the international IMI2 project “Translational Safety Biomarker Pipeline”

Early and reliable detection and monitoring of adverse events is essential for improving of patient safety, reducing late attrition of drug candidates, and enhancing understanding of toxic mechanisms. The Translational Safety Biomarker Pipeline (TransBioLine) project will focus on development of biomarkers of injury for liver, kidney, pancreas, vasculature, central nervous system (CNS) and the development of non-invasive microRNA biomarkers using liquid biopsies. The project is coordinated by the University of Zurich with Pfizer as industry lead, and involves 27 partners (pharmaceutical companies, small and medium-sized enterprises, and academic institutions) from ten European countries and the United States of America. With a total budget of € 28 million, the EU and the pharmaceutical companies involved are financing the [...]

Read More
30 04, 2019

TAmiRNA and advanceCOR receive Eurostars project “thrombomiR”

2023-03-10T11:01:46+01:00April 30th, 2019|biomarkers, drug development, drug discovery, microRNAs, Personalized medicine, safety, thrombomiR|Comments Off on TAmiRNA and advanceCOR receive Eurostars project “thrombomiR”

TAmiRNA and advanceCOR, a drug developing biotechnology company which focuses on personalized medicine in cardiovascular diseases, receive Eurostars project entitled: ”A novel microRNA-based platelet function biomarker for personalized anti-thrombotic treatment”.  The aim of the Eurostars project is to validate the use of the thrombomiR™ kit for management of anti-thrombotic therapies. The thrombomiR™ kit is a minimally invasive blood test that can determine changes in platelets reactivity (for example due to a therapy), based on the quantitative analysis of microRNAs, Specifically, the thrombomiR™ kit allows the targeted detection and quantitation of platelet-specific microRNAs in blood plasma. The concentration of these microRNAs increases in the course of activation of platelets and decreases as a result of therapeutic inactivation. Thus, [...]

Read More
23 01, 2018

TAmiRNA & Vivomicx announce the introduction of new technology to make preclinical drug discovery and drug development more efficient.

2023-03-10T11:00:13+01:00January 23rd, 2018|biomarkers, drug development, drug discovery, LMD, microRNA, microRNAs, Vivomicx|Comments Off on TAmiRNA & Vivomicx announce the introduction of new technology to make preclinical drug discovery and drug development more efficient.

TAmiRNA & Vivomicx have combined their technologies of laser microdissection and high sensitivity qPCR, which enables the quantitative analysis of cell-type specific RNA expression in complex tissues. Using this protocol TAmiRNA & Vivomicx have already been able to demonstrate: the profound difference of RNA expression between whole tumor and subsets of cells within the tumor and the large heterogeneity in RNA expression between colorectal* tumor compartments such as tumor, stroma and tumor endothelial cells. * Note: the technology can be utilized for almost any tissue sample. The combination of Vivomicx and TAmiRNA´s proprietary protocols is clearly superior to the current standard where only whole tumor material is analyzed, and marks another step on the road to make the [...]

Read More
© Copyright TAmiRNA 2019 - 
 
Go to Top